The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing SLE is one of the most prevalent and ...
Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platform ii,iii,iv,v Additional VARIPULSE Platform data presented at AF ...
InvestorsHub on MSN
Johnson & Johnson presents three-year TREMFYA data showing sustained ulcerative colitis outcomes
Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to ...
Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...
--Longest winning streak since Oct. 12, 2017, when it rose for 10 straight trading days --Best 10 day stretch since the 10 days ending April 22, 2020, when it rose 11.28% --Up 5.24% this week; best ...
The VARIPULSE Platform is Johnson & Johnson MedTech's Pulsed Field ablation system. The fully integrated platform includes the VARIPULSE Catheter, TRUPULSE Generator, and CARTO 3 Mapping System ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results